Core Insights - Cognition Therapeutics, Inc. reported positive results from the exploratory Phase 2 SHIMMER study, indicating that CT1812 showed strong therapeutic responses in patients with dementia with Lewy bodies (DLB) across various measures [1][2] Study Results - The SHIMMER Phase 2 study involved 130 patients with mild-to-moderate DLB, who were randomized to receive either CT1812 or placebo for six months [1] - The study met its primary endpoint of safety and tolerability, with DLB patients treated with CT1812 showing significant improvements in behavioral, functional, cognitive, and movement measures compared to placebo [2] - There was an 82% slowing in the total neuropsychiatric inventory (NPI), with notable reductions in anxiety, hallucinations, and delusions among CT1812 treated patients [2] - Caregiver distress also saw a marked reduction, indicating a positive impact on the daily lives of patients receiving the drug [3] - Participants treated with CT1812 experienced a 91% decline in fluctuations in attention, demonstrating a slowing decline across all three cognitive measures compared to placebo [3] Financial Position - As of September 30, 2024, Cognition Therapeutics reported cash and cash equivalents of approximately $22.0 million, with total grant funds remaining from the NIA at $53.6 million [5] - The company estimates it has sufficient cash to fund operations and capital expenditures into the second quarter of 2025 [5] Stock Performance - Following the positive study results, CGTX stock increased by 93.45%, reaching $0.88 [6]

Clinical Trial Results - CT1812 demonstrated strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with dementia with Lewy bodies (DLB) in the exploratory Phase 2 SHIMMER study [1] - The study met its primary endpoint of safety and tolerability, with CT1812-treated patients showing improvement in behavioral, functional, cognitive, and movement measures compared to placebo [2] - There was an 82% slowing in the total neuropsychiatric inventory (NPI), with significant reductions in anxiety, hallucinations, and delusions in the CT1812-treated arms [2] - Participants treated with CT1812 experienced a 91% slowing in the decline of attention fluctuations compared to placebo [2] Study Design and Details - The SHIMMER Phase 2 study enrolled 130 patients with mild-to-moderate DLB, randomized to receive one of two oral doses of CT1812 or placebo daily for six months [2] - The study is supported by a $30 million grant from the National Institute on Aging of the National Institutes of Health (NIH) [8] - The study is being conducted at over 30 sites in the United States, many of which are Lewy Body Dementia Association (LBDA) centers of excellence [8] Future Plans and Expectations - Cognition Therapeutics plans to advance CT1812 into late-stage trials based on the positive results from the SHIMMER study [1] - The company will present detailed data at the International Lewy Body Dementia Conference (ILBDC) in January 2025 [2] - Cognition Therapeutics will review the topline efficacy and safety findings with the FDA in an end-of-Phase 2 meeting [3] About CT1812 - CT1812 is an experimental orally delivered small molecule oligomer antagonist that penetrates the blood-brain barrier and binds selectively to the sigma-2 (σ-2) receptor complex [10] - CT1812 is currently being investigated in clinical programs for Alzheimer’s disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD) [12] About Dementia with Lewy Bodies (DLB) - DLB is the second most common cause of dementia, affecting an estimated 1.4 million Americans [6] - The disease is caused by a buildup of the protein α-synuclein, which aggregates in Lewy bodies within brain neurons [6] - DLB disrupts biological processes affecting autonomic, digestive, cognitive, and motor systems, leading to symptoms such as hallucinations, delusions, and movement disorders [6]

Core Viewpoint - Cognition Therapeutics, Inc. (CGTX) has experienced a bearish price trend recently, losing 9.6% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottom in the stock price, suggesting that selling pressure may be exhausting and that bulls could be gaining control [2][4]. - A hammer pattern forms when there is a small candle body with a long lower wick, typically occurring during a downtrend, signaling a possible reversal if it appears at the bottom of the trend [3][4]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for CGTX, which is a bullish indicator that could lead to price appreciation in the near term [6]. - The consensus EPS estimate for CGTX has increased by 14.1% over the last 30 days, indicating that analysts expect better earnings than previously predicted [7]. - CGTX holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [8].

– Topline results in second dementia indication expected to be reported in December 2024 – PURCHASE, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the last patient has completed their final clinic visit in the Phase 2 SHIMMER study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB). The Company anticipates that topline results will be available in ...

Core Insights - Cognition Therapeutics, Inc. reported a 95% reduction in cognitive decline in patients treated with CT1812 who had lower plasma p-tau217 levels, indicating the drug's potential to modify the disease progression of Alzheimer's [1][2][3] Group 1: Study Findings - The Phase 2 'SHINE' study involved 153 adults with mild-to-moderate Alzheimer's disease, focusing on safety, tolerability, and cognitive function [4] - Participants with lower plasma p-tau217 levels experienced a 2.7-point improvement on the ADAS-Cog11 scale compared to placebo over six months [2][4] - Key biomarkers reflecting Alzheimer's disease pathology showed normalization in CT1812-treated participants, including reductions in GFAP, NfL, Aβ42, and Aβ40 [3][4] Group 2: Future Plans - The company plans to present comprehensive biomarker results at scientific conferences in 2025 and intends to meet with the FDA to discuss the findings and Phase 3 program design [3][4] - Ongoing recruitment for the START study and completed enrollment in the SHIMMER study indicate the company's commitment to advancing CT1812's clinical development [9][10] Group 3: About CT1812 - CT1812 is an experimental small molecule that targets the sigma-2 receptor complex, aiming to displace toxic Aβ oligomers and regulate cellular processes affected by Alzheimer's disease [8] - The median baseline level of plasma p-tau217 in the SHINE study was found to be 1.0 pg/mL, with participants categorized based on levels above or below this median [6][7]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40886 Cognition Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 13-436 ...

Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update - CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to report topline results from Phase 2 SHIMMER study investigating CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB) by end of 2024 - Purchase, NY – November 13, 20 ...

Clinical Trial Progress - CT1812 demonstrated a 95% slowing of cognitive decline on the ADAS-Cog11 scale and a 108% slowing on the MMSE scale in Alzheimer's disease patients with baseline p-tau217 levels below the median in the Phase 2 SHINE study [1][3] - The Phase 2 SHIMMER study investigating CT1812 in mild-to-moderate dementia with Lewy bodies (DLB) is on track to report topline results by the end of 2024 [1][2] - Enrollment continues in the Phase 2 START study for early Alzheimer's disease and the Phase 2 MAGNIFY study for geographic atrophy secondary to dry age-related macular degeneration [3] Financial Performance - Cash and cash equivalents as of September 30, 2024, were approximately $22.0 million, with $53.6 million in remaining grant funds from the NIA, sufficient to fund operations into Q2 2025 [4] - Research and development expenses decreased to $11.4 million in Q3 2024 from $11.7 million in Q3 2023, primarily due to lower costs with contract manufacturing organizations [5] - General and administrative expenses remained stable at $3.1 million in Q3 2024 compared to the same period in 2023 [6] - The company reported a net loss of $9.9 million, or $(0.25) per share, in Q3 2024, compared to a net loss of $6.7 million, or $(0.22) per share, in Q3 2023 [7] Strategic and Corporate Updates - The company plans to request an end-of-Phase 2 meeting with the FDA to review CT1812's safety, tolerability, and results from the SHINE study, aiming to align on a pivotal Phase 3 program design [2] - DLB, the second most common neurodegenerative disease, lacks disease-modifying treatments, and the SHIMMER study aims to provide safety and tolerability data for this under-studied population [2] - The company presented baseline characteristics of participants in the Phase 2 SHIMMER study at the CTAD conference, confirming enrollment of individuals with mild-to-moderate DLB [3]

- Patient characteristics are consistent with other DLB studies - PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented participant baseline characteristics in the Phase 2 ‘SHIMMER’ study of mild-to-moderate dementia with Lewy bodies (DLB). The poster is being presented at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference ...

- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology - - ADAS-Cog 11 scores showed 95% slowing of decline - - MMSE scores showed 108% slowing of decline - - Pre-specified analysis from SHINE study presented by Dr. Michael Woodward at CTAD 2024 - - Company hosting investor webinar on October 30, 2024 to review findings - PURCHASE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc ...